Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Approved For Marketing No phase listed Expanded access

Expanded Access of Adagrasib (MRTX849) in Patients With Advanced Solid Tumors Who Have a KRAS G12C Mutation

ClinicalTrials.gov ID: NCT05162443

Public ClinicalTrials.gov record NCT05162443. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 21, 2026, 11:24 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Expanded Access Use of Adagrasib (MRTX849) for the Treatment of Patients With Advanced Solid Tumors With a KRAS G12C Mutation

Study identification

NCT ID
NCT05162443
Recruitment status
Approved For Marketing
Study type
Expanded access
Phase
Not listed
Lead sponsor
Bristol-Myers Squibb
Industry
Enrollment
Not listed

Conditions and interventions

Interventions

  • adagrasib (MRTX849) Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Not listed

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Not listed
Primary completion
Not listed
Completion
Not listed
Last update posted
Aug 25, 2025

United States locations

U.S. sites
11
U.S. states
9
U.S. cities
11
Facility City State ZIP Site status
California Pacific Medical Center San Francisco California 94115
Providence Medical Group Santa Rosa - Cancer Center Santa Rosa California 95403
Hartford Hospital Hartford Connecticut 06106
Piedmont Cancer Institute Atlanta Georgia 30318
Mayo Clinic - Rochester Rochester Minnesota 55905
Renown Health Reno Nevada 89502
Lehigh Valley Cancer Institute Allentown Pennsylvania 18103
Lumi Research Kingwood Texas 77339
Virginia Cancer Institute Richmond Virginia 23230
Seattle Integrative Cancer Center Renton Washington 98057
Swedish Cancer Institute Seattle Washington 98104

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05162443, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 25, 2025 · Synced Jul 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05162443 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →